AMEVIVE® Pregnancy Registry

Astellas Pharma Inc3 enrolled

Overview

This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE® in order to detect any potential increase in the risk of major birth defects. The AMEVIVE® Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).

Prospective reports will be collected from pregnant subjects, health care provider (HCP), or Astellas Product Safety Management staff. Data from the pregnant subjects will be collected at 4 to 5 months of pregnancy by telephone interviews with the Registry. The Registry will also contact the subject at 2 months and 12 months after the estimated delivery date (EDD) for post-natal \& pediatric follow-up. The Registry will confirm the information collected from the subject with the HCP by telephone interviews with the Registry, forms mailed/faxed to the Registry, electronic forms/queries sent to the Registry, or a combination of these methods. If a live birth is reported, the infant's HCP will be contacted for the Pediatric Follow-Up at 2 months and 12 months of age. If a birth defect is reported, targeted follow-up will be conducted.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pregnancy

Interventions

Amevive exposureDRUG

Observational

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Have been exposed to AMEVIVE® within 8 weeks prior to conception or at any time during pregnancy * Provide sufficient information to determine that the pregnancy is prospectively registered (i.e., the outcome of pregnancy must be unknown prospectively) * Provide verbal consent to participate in the Registry, and * Verbally provide the contact information for herself, her healthcare provider (HCP), and the infant's HCP (if applicable) Exclusion Criteria: * None

Locations (1)

INC Research

Wilmington, North Carolina, United States

Outcomes

Primary Outcomes

Evaluate pattern or increase in major birth defects in children of women w/ psoriasis who were exposed to AMEVIVE® at any time within the 8 wks prior to conception, or at any time during pregnancy, where outcome of the pregnancy is unknown prospectively

Time frame: At month 4 to 5 of pregnancy; At 2 months and 12 months post estimated delivery date

Secondary Outcomes

To evaluate the number of live born infants versus fetal loss in pregnant women exposed to AMEVIVE®

Time frame: At 2 months post estimated delivery date

To evaluate gestational age, body weight, gender, head circumference, and body length in live born infants exposed to AMEVIVE®

Time frame: At 2 months post estimated delivery date

To evaluate appearance, pulse, grimace, activity, and respiration (APGAR) scores at 1 and 5 minutes of age in live born infants exposed to AMEVIVE®

Time frame: At 2 months post estimated delivery date

To evaluate hospitalizations for infection in live born infants exposed to AMEVIVE®

Time frame: At 2 months and 12 months post estimated delivery date

To evaluate clinically significant infections with unusual organisms, not requiring hospitalization in live born infants exposed to AMEVIVE®

Time frame: At 2 months and 12 months post estimated delivery date

To evaluate malignancies in live born infants exposed to AMEVIVE®

Time frame: At 2 months and 12 months post estimated delivery date

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.